| Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. | |
| | |
MedLine Citation:
|
PMID: 18082493 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Pentraxin 3 (PTX3) is a novel inflammatory marker produced by endothelial cells, smooth muscle cells, and macrophages. The purpose of the present study was to examine the clinical significance of plasma PTX3 levels in patients with heart failure. METHODS: We measured the plasma PTX3 levels in 196 patients with heart failure and 60 control subjects without heart failure by sandwich enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 655 days with the end points of cardiac death or progressive heart failure requiring rehospitalization. RESULTS: Plasma PTX3 concentrations were higher in patients with heart failure than in control subjects (P < .0001) and increased as the severity of New York Heart Association functional class advanced (P < .0001). A total of 63 cardiac events occurred during a follow-up period, and cardiac event-free rate was markedly lower in patients with high PTX3 levels than in those with normal PTX3 levels (44.7% vs 89.2%, P < .0001). The multivariate Cox proportional hazard analysis demonstrated that the plasma PTX3 level, but not the high-sensitive C-reactive protein, was the independent predictor of cardiac events (hazard ratio 1.20, 95% CI 1.03-1.40, P = .0162). Patients were divided into 4 groups based on plasma PTX3 values from first to fourth quartile. The highest fourth quartile of plasma PTX3 levels was associated with the highest risk of cardiac events (9.23-fold compared with the first quartile). CONCLUSIONS: The plasma PTX3 level provides important prognostic information for the risk stratification of patients with heart failure. |
| | |
Authors:
|
Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota |
Related Documents
:
|
445953 - Disopyramide kinetics in patients with acute myocardial infarction. 17380223 - Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in dete... 22660923 - Heart failure with a normal ejection fraction: treatments for a complex syndrome? |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-09-27 |
Journal Detail:
|
Title: American heart journal Volume: 155 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-17 Completed Date: 2008-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 75-81 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over C-Reactive Protein / analysis* Case-Control Studies Disease Progression Female Heart Failure / blood, diagnosis*, mortality* Humans Inflammation Mediators / blood* Male Middle Aged Predictive Value of Tests Probability Prognosis Proportional Hazards Models Reference Values Risk Assessment Sensitivity and Specificity Serum Amyloid P-Component / analysis* Severity of Illness Index Statistics, Nonparametric Survival Analysis Vasculitis / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Inflammation Mediators; 0/Serum Amyloid P-Component; 148591-49-5/PTX3 protein; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an in...
Next Document: Cystatin C and risk of heart failure in the Physicians' Health Study (PHS).